SE190079C1 - - Google Patents
Info
- Publication number
- SE190079C1 SE190079C1 SE190079DA SE190079C1 SE 190079 C1 SE190079 C1 SE 190079C1 SE 190079D A SE190079D A SE 190079DA SE 190079 C1 SE190079 C1 SE 190079C1
- Authority
- SE
- Sweden
- Prior art keywords
- kanamycin
- phenylsalicylate
- solution
- base
- excreted
- Prior art date
Links
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 35
- 229960000969 phenyl salicylate Drugs 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- ZJWUEJOPKFYFQD-UHFFFAOYSA-N 2-hydroxy-3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O ZJWUEJOPKFYFQD-UHFFFAOYSA-N 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 description 16
- 229930182823 kanamycin A Natural products 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 229930027917 kanamycin Natural products 0.000 description 11
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229960001192 bekanamycin Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 3
- SKKLOUVUUNMCJE-FQSMHNGLSA-N kanamycin B Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SKKLOUVUUNMCJE-FQSMHNGLSA-N 0.000 description 3
- 229930182824 kanamycin B Natural products 0.000 description 3
- 229960002064 kanamycin sulfate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE190079T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE190079C1 true SE190079C1 (cs) | 1964-01-01 |
Family
ID=41976794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE190079D SE190079C1 (cs) |
Country Status (1)
| Country | Link |
|---|---|
| SE (1) | SE190079C1 (cs) |
-
0
- SE SE190079D patent/SE190079C1/sv unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1208844B1 (en) | The use of glycyrrhizin for treating mastitis. | |
| RU2669800C2 (ru) | Способы лечения воспаления, аутоиммунных расстройств и боли | |
| CZ286821B6 (en) | Use of fumagillol or ester thereof for preparing medicaments intended for fighting intestinal infections | |
| EP1207868A1 (de) | Pharmazeutische tramadolsalze | |
| KR850000065B1 (ko) | 린코마이신 및 클린다마이신의 제조방법 | |
| DE19932555A1 (de) | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen | |
| DE69433012T2 (de) | Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac | |
| US4076804A (en) | Erythromycin therapy | |
| SE190079C1 (cs) | ||
| US3949077A (en) | Synergistic antibiotic compositions | |
| JPS6335635B2 (cs) | ||
| DE2559989B1 (de) | Polymere und Verfahren zu ihrer Herstellung | |
| DE2950154C2 (cs) | ||
| US3642987A (en) | Lincomycin and tetracycline compositions | |
| DE3034975A1 (de) | Arzneimittelkombination zur behandlung infektioeser atemwegerkrankungen | |
| WO2023221854A1 (zh) | 一种抗寄生虫感染的口服药物制剂及其制备方法和应用 | |
| US3087858A (en) | Kanamycin 3-phenylsalicylate | |
| US3940481A (en) | Treatment of hepatic coma with isomaltitol | |
| EP1038526A1 (de) | Behandlung von funktionellen Störungen der unteren Darmwege und einhergehenden visceralen Schmerzen mit Moxonidin | |
| DE69114261T2 (de) | Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit. | |
| DE2265235A1 (de) | Heilmittel | |
| EP0123157A1 (de) | Arzneimittel und/oder Futtermittelkonzentrate mit antibakterieller Wirkung | |
| SE8502039D0 (sv) | New drug compositions of antimicrobial activity and process for their preparation | |
| US20220409651A1 (en) | Anti-fungal compositions and methods for using same | |
| US3546207A (en) | Neomycin citrate |